{"disease":{"id":"la-hnscc","name":"la hnscc"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05176483","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT04141449","title":"A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":874,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT07246759","title":"Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"OncoHost Ltd.","has_results":false},{"nct_id":"NCT06725342","title":"HNSCC Immuno-genomics Project","phase":"","overall_status":"COMPLETED","enrollment_count":401,"lead_sponsor_name":"Hellenic Cooperative Oncology Group","has_results":false},{"nct_id":"NCT04157985","title":"Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":161,"lead_sponsor_name":"Dan Zandberg","has_results":false},{"nct_id":"NCT03744468","title":"Study of Surzebiclimab (BGB-A425) and Alcestobart (LBL-007) in Combination With Tislelizumab in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":147,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT03739931","title":"Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":134,"lead_sponsor_name":"ModernaTX, Inc.","has_results":false},{"nct_id":"NCT04354246","title":"COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":110,"lead_sponsor_name":"Compugen Ltd","has_results":false},{"nct_id":"NCT06755762","title":"Using a 3D Culture Model for Circulating Tumor Cells Combined With Molecular Bioassays in Patients With HNSCC Cancer","phase":"","overall_status":"RECRUITING","enrollment_count":88,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT03107182","title":"Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":72,"lead_sponsor_name":"University of Chicago","has_results":true},{"nct_id":"NCT04114136","title":"Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":72,"lead_sponsor_name":"Dan Zandberg","has_results":false},{"nct_id":"NCT05859074","title":"A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT06978829","title":"Cetuximab + Tislelizumab + Chemotherapy in the Treatment of Unresectable LA HNSCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":42,"lead_sponsor_name":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","has_results":false},{"nct_id":"NCT03944915","title":"De-Escalation Therapy for Human Papillomavirus Negative Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"University of Chicago","has_results":true},{"nct_id":"NCT04370587","title":"A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"ImmVira Pharma Co. Ltd","has_results":false},{"nct_id":"NCT06722495","title":"Efficacy and Safety of a Third-Course of Neoadjuvant Immunochemotherapy Combined With SBRT in Locally Advanced Head and Neck Squamous Cell Carcinoma Patients With Stable Disease After Two Treatment Courses: A Single-Arm Exploratory Study","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT07106827","title":"A Study of GV20-0251 in Advanced or Refractory Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":10,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT06090318","title":"Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Rain Oncology Inc","has_results":false}],"total":18},"guidelines":[],"source":"Drug Landscape verified database"}